TriGemX Bio
PrivateLast Round
Early Funding
Oct 2, 2026
Est. Valuation
$1.27B
Total Funding Raised
$581.2M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
TriGemX Bio is a biotechnology company focused on developing elismetrep, a first-in-class TRPM8 channel blocker for the treatment of migraine.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TriGemX Bio Comparables
Compare TriGemX Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nura Bio | 64% | |
| Latigo Biotherapeutics | 59% | |
| RaQualia Pharma, Inc. | 50% |
TriGemX Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Oct 2, 2026 | ||||
| Grant | May 10, 2023 | ||||
| Series D | Feb 15, 2022 | ||||
| Series C | Mar 25, 2020 | ||||
| Series B | Dec 5, 2018 | ||||
Series A | Dec 10, 2015 |
TriGemX Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series A, Series B, Series C, Early Funding, Series D |
| TCG Crossover | Early Funding |
| Greenspring Associates | Series C |
| Parkwood | Series D |
| StepStone Group | Series D |
| Lux Capital | Series A, Series B, Series D, Series C |
| Gates Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 2, 2026
$94M raised with Viking Global Investors, TCG Crossover, and The Column Group leading.
- May 10, 2023
Received $8.2M from the Gates Foundation.
Recent news
Latest coverage and updates
- hiresOct 5, 2026
On Oct 5th '26, TriGemX Bio, a biotechnology company developing a first-in-class migraine medicine, announces Doug Pagán's appointment to its Board of Directors.
- is_developingOct 1, 2026
TriGemX Bio is developing elismetrep, an investigational oral TRPM8 channel blocker in Phase 3 for the acute treatment of migraine, in New York.
- hiresOct 1, 2026
TriGemX Bio appoints biotech veteran Aninda Katragadda as Chief Financial Officer as it relaunches under a new name and advances elismetrep for migraine treatment on Oct 1st '26.
- receives_financingOct 1, 2026
On Oct 1st '26, TriGemX Bio closes a $94M financing co-led by The Column Group, TCGX, and Viking Global Investors to advance elismetrep's Phase 3 clinical development for acute migraine.
- hiresOct 1, 2026
TriGemX Bio appoints biotech veteran Jeff Goater as Chief Executive Officer in Oct '26, alongside Aninda Katragadda as Chief Financial Officer and Brett Lauring as Chief Medical Officer.
TriGemX Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about TriGemX Bio's valuation, stock price, and market status.
Is TriGemX Bio a public or private company?
TriGemX Bio is a private company.
What is the current stock price of TriGemX Bio?
TriGemX Bio is a private company, so its shares have no public market price. Caplight tracks TriGemX Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TriGemX Bio worth (valuation)?
TriGemX Bio's valuation is estimated at $1.3B based on funding round data.
Can I buy TriGemX Bio stock?
TriGemX Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TriGemX Bio's last funding round?
TriGemX Bio's most recent funding round was Early Funding on October 2, 2026.
Who are the main investors in TriGemX Bio?
Key investors in TriGemX Bio include The Column Group, TCG Crossover, Viking Global Investors, Mubadala Investment Company.
Will TriGemX Bio IPO soon?
No public IPO plans have been announced for TriGemX Bio.
How can I track TriGemX Bio secondary market activity?
Caplight tracks bids, offers, and trades in TriGemX Bio's shares on secondary markets.